Global Biologics Market—Companies-to-Action

Global Biologics Market—Companies-to-Action

Biopharma Companies are Increasingly Collaborating with CDMOs, CROs, and Digital and Medical Equipment Companies for Biologics Discovery and Development

RELEASE DATE
20-Nov-2017
REGION
North America
Research Code: MD83-01-00-00-00
SKU: HC02925-NA-MR_21137
$3,000.00
In stock
SKU
HC02925-NA-MR_21137
$3,000.00
Links

Pay by invoice

ENQUIRE NOW

Description

This study on the "Global Biologics Market: Companies-to-Action" presents an overview of the global biologics landscape with an emphasis on the top 10 leading bio-pharma companies in the market. The study highlights the shifting focus and investments of bio-pharma companies towards biologics discovery and development, which is attributed to the growing demand for innovative therapies as well as the loss of patent exclusivity of the leading pharma products. Across therapy areas, oncology and diabetes emerge as the key contributing segments alongside immunology and cardiovascular diseases. Several small- to mid-sized companies are increasingly focusing on oncology and immunology segments which have high unmet needs and higher acceptability for innovative therapies. Furthermore, across the biologics sub-segments, monoclonal antibodies (mAb) and bioengineered vaccines are amongst the highest contributing segments, with most companies having a strong focus on developing a mAb pipeline. On the other hand, cell and gene therapy are expected to show a strong potential, especially across the rare diseases market, with leading companies like Amgen, Sanofi, Pfizer, etc., investing in molecules in the early stages of clinical development. These molecules, if approved, have the potential of becoming key blockbuster products, propelling the market by more than 20% in the next few years. To achieve expertise across specific therapy areas and biologic sub-segments, bio-pharma companies collaborate with Contract Development and Manufacturing Organizations (CDMOs), Contract Research Organizations (CROs), and digital and medical equipment companies that provide access to innovative proprietary technologies for research and development activities and to optimize the manufacturing process of complex biologics. Alongside industry and academic research collaborations, companies are also focusing on partnering with IT players such as IBM Watson, Intel etc., which provide technologically advanced solutions for conducting clinical trials to support complex drug manufacturing processes, thus creating integrated business models in addition to the above mentioned strategic analysis, a detailed biologic product pipeline, and a SWOT analysis of the key players has been undertaken.

Some of the key questions answered by the study include:
•     What are the current growth opportunities in biologics? What is the impact of the external environment on this market?
•     Which are the leading companies that are introducing new and innovative products in the market?
•     How do these companies intend to transform the industry paradigms in the next five years?
•     What is their strategic focus and potential for growth?
•     What are the key strategic imperatives in the biologics market?
•     What are the key strategic collaborations/partnerships and investments made by the companies to stay on the growth trajectory?

RESEARCH: INFOGRAPHIC

This infographic presents a brief overview of the research, and highlights the key topics discussed in it.
Click image to view it in full size

Table of Contents

Key Findings—Analysis of Companies-2-Action

Scope and Segmentation

Companies to Action Value Creators

Opportunities and Threats

10 Leading Biopharma Companies to Watch

Roche—Product Portfolio Overview

Roche—Key Biologic Product Pipeline

Roche SWOT Analysis

Amgen—Product Portfolio Overview

Amgen—Key Biologic Product Pipeline

Amgen SWOT Analysis

Sanofi —Product Portfolio Overview

Sanofi —Key Biologic Product Pipeline

Sanofi SWOT Analysis

Abbvie —Product Portfolio Overview

Abbvie —Key Biologic Product Pipeline

Abbvie SWOT Analysis

Novo Nordisk —Product Portfolio Overview

Novo Nordisk —Key Biologic Product Pipeline

Novo Nordisk SWOT Analysis

Merck & Co —Product Portfolio Overview

Merck & Co —Key Biologic Product Pipeline

Merck & Co SWOT Analysis

Pfizer —Product Portfolio Overview

Pfizer —Key Biologic Product Pipeline

Pfizer SWOT Analysis

Johnson & Johnson (JNJ)—Product Portfolio Overview

Johnson & Johnson (JNJ)—Key Biologic Product Pipeline

Johnson & Johnson (JNJ) SWOT Analysis

Eli Lilly—Product Portfolio Overview

Eli Lilly—Key Biologic Product Pipeline

Eli Lilly SWOT Analysis

GlaxoSmithKline (GSK)—Product Portfolio Overview

GlaxoSmithKline (GSK)—Key Biologic Product Pipeline

GlaxoSmithKline (GSK) SWOT Analysis

Business Models in Biologics Market

Competitive Playbook—Market Share Analysis

Top 10 Biologics in the Market

Top 10 Biologics Companies

Key Merger, Acquisition & Partnership Agreements

Key Investments and Facility Expansions

Transformation in Industry Ecosystem

5 Major Growth Opportunities

Strategic Imperatives for Biologics Market

Conclusion—Key Take Aways

Legal Disclaimer

List of Abbreviations

List of Figures
  • 1. Biologics C2A: C2A Value Creators, Global, 2017
  • 2. Roche: Key Marketed Biologics, Global, 2016
  • 3. Amgen: Key Marketed Biologics, Global, 2016
  • 4. Sanofi: Key Marketed Biologics, Global, 2016
  • 5. Abbvie: Key Marketed Biologics, Global, 2016
  • 6. Novo Nordisk: Key Marketed Biologics, Global, 2016
  • 7. Global Biologics Market: Merck &Co, Key Marketed Products, Global, 2016
  • 8. Global Biologics Market: Pfizer, Key Marketed Biologics, Global, 2016
  • 9. Johnson & Johnson: Key Marketed Biologics, Global, 2016
  • 10. Eli Lilly: Key Marketed Biologics, Global, 2016
  • 11. GlaxoSmithKline: Key Marketed Biologics, Global, 2016
  • 12. Total Biologics Market: Business Models, 2016
  • 13. Total Biologics Market: Major Biologic Products, Global, 2016
  • 14. Total Biologics Market: Leading Biologic Companies, Global, 2015
  • 15. Total Biologics Market: Key Mergers and Acquisitions, Global, 2016-2017
  • 16. Total Biologics Market: Facility Expansions and Investments, Global, 2016-17
  • 17. Global Biologics Market: Major Growth Opportunities, Global, 2016–2021
List of Charts
  • 1. Roche: Key Marketed Biologics, Global, 2016
  • 2. Roche: Biologics by Development Phase, Global, 2017
  • 3. Roche: Key Products in Development by Biologic Sub-segment, Global, 2017
  • 4. Roche: Key Products in Development by Therapeutic Area, Global, 2017
  • 5. Amgen: Key Marketed Biologics, Global, 2016
  • 6. Amgen: Biologics by Development Phase, Global, 2017
  • 7. Amgen: Key Products in Development by Biologic Sub-segment, Global, 2017
  • 8. Amgen: Key Products in Development by Therapeutic Area, Global, 2017
  • 9. Sanofi: Key Marketed Biologics, Global, 2016
  • 10. Sanofi: Biologics by Development Phase, Global, 2017
  • 11. Sanofi: Key Products in Development by Biologic Sub-segment, Global, 2017
  • 12. Sanofi: Key Products in Development by Therapeutic Area, Global, 2017
  • 13. Abbvie: Key Marketed Biologics, Global, 2016
  • 14. Abbvie: Biologics by Development Phase, Global, 2017
  • 15. Abbvie: Key Products in Development by Biologic Sub-segment, Global, 2017
  • 16. Abbive: Key Products in Development by Therapeutic Area, Global, 2017
  • 17. Novo Nordisk: Key Marketed Biologics, Global, 2016
  • 18. Novo Nordisk: Biologics by Development Phase, Global, 2017
  • 19. Novo Nordisk: Products in Development by Biologic Sub-segment, Global, 2017
  • 20. Novo Nordisk: Key Products in Development by Therapeutic Area, Global, 2017
  • 21. Merck & Co: Key Marketed Biologics, Global, 2016
  • 22. Merck & Co: Biologics by Development Phase, Global, 2017
  • 23. Merck & Co: Key Products in Development by Biologic Sub-segment, Global, 2017
  • 24. Merck & Co: Key Products in Development by Therapeutic Area, Global, 2017
  • 25. Pfizer: Key Marketed Biologics, Global, 2016
  • 26. Pfizer: Biologics by Development Phase, Global, 2017
  • 27. Pfizer: Products in Development by Biologic Sub-segment, Global, 2017
  • 28. Pfizer: Key Products in Development by Therapeutic Area, Global, 2017
  • 29. "Johnson & Johnson: Key Marketed Biologics, Global, 2016"
  • 30. Johnson & Johnson: Biologics by Development Phase, Global, 2017
  • 31. Johnson & Johnson: Products in Development by Biologic Sub-segment, Global, 2017
  • 32. Johnson & Johnson: Key Products in Development by Therapeutic Area, Global, 2017
  • 33. Eli Lilly: Key Marketed Biologics, Global, 2016
  • 34. "Eli Lilly: Biologics by Development Phase, Global, 2017"
  • 35. Eli Lilly: Key Products in Development by Biologic Sub-segment, Global, 2017
  • 36. Eli Lilly: Key Products in Development by Therapeutic Area, Global, 2017
  • 37. GlaxoSmithKline: Key Marketed Biologics, Global, 2016
  • 38. GlaxoSmithKline: Biologics by Development Phase, Global, 2017
  • 39. GlaxoSmithKline: Products in Development by Biologic Sub-segment, Global, 2017
  • 40. GlaxoSmithKline: Key Products in Development by Therapeutic Area, Global, 2017
  • 41. Global Pharmaceutical Market: Top Ten Drugs by Sales, Global, 2016
  • 42. Total Genset Market for Water and Wastewater Treatment Plants: Revenue Breakdown by Genset Type, Global, 2016 and 2021
Related Research

Growth Insights—Real World Evidence Analytics Solutions Market

Release Date: 24-Apr-18
Region: North America

East African Pharmaceutical Market, Forecast to 2021

Release Date: 27-Sep-17
Region: Africa

Global CRO Market, Forecast to 2021

Release Date: 19-Apr-17
Region: Asia Pacific

Biomarkers Enabling Diabetes and Obesity Management

Release Date: 02-Mar-17
Region: Global

2016 Indonesia Transformational Health Insights

Release Date: 31-May-2016
Region: Asia Pacific

Pharmaceutical Market Access Strategy for Ethiopia

Release Date: 27-May-2016
Region: Africa

Vital Signs The Analyst's Perspective - April 2016 Issue

Release Date: 24-May-2016
Region: Global
This study on the "Global Biologics Market: Companies-to-Action" presents an overview of the global biologics landscape with an emphasis on the top 10 leading bio-pharma companies in the market. The study highlights the shifting focus and investments of bio-pharma companies towards biologics discovery and development, which is attributed to the growing demand for innovative therapies as well as the loss of patent exclusivity of the leading pharma products. Across therapy areas, oncology and diabetes emerge as the key contributing segments alongside immunology and cardiovascular diseases. Several small- to mid-sized companies are increasingly focusing on oncology and immunology segments which have high unmet needs and higher acceptability for innovative therapies. Furthermore, across the biologics sub-segments, monoclonal antibodies (mAb) and bioengineered vaccines are amongst the highest contributing segments, with most companies having a strong focus on developing a mAb pipeline. On the other hand, cell and gene therapy are expected to show a strong potential, especially across the rare diseases market, with leading companies like Amgen, Sanofi, Pfizer, etc., investing in molecules in the early stages of clinical development. These molecules, if approved, have the potential of becoming key blockbuster products, propelling the market by more than 20% in the next few years. To achieve expertise across specific therapy areas and biologic sub-segments, bio-pharma companies collaborate with Contract Development and Manufacturing Organizations (CDMOs), Contract Research Organizations (CROs), and digital and medical equipment companies that provide access to innovative proprietary technologies for research and development activities and to optimize the manufacturing process of complex biologics. Alongside industry and academic research collaborations, companies are also focusing on partnering with IT players such as IBM Watson, Intel etc., which provide technologically ad
More Information
No Index No
Podcast No
Table of Contents | Executive Summary~ || Key Findings—Analysis of Companies-2-Action~ || Scope and Segmentation~ | Companies-to-Action Overview~ || Companies to Action Value Creators~ || Opportunities and Threats~ || 10 Leading Biopharma Companies to Watch~ | Key Biologics Companies Product Pipeline Analysis—Roche: Biologic Product Pipeline Analysis~ || Roche—Product Portfolio Overview~ || Roche—Key Biologic Product Pipeline~ || Roche SWOT Analysis~ | Amgen—Biologic Product Pipeline Analysis ~ || Amgen—Product Portfolio Overview~ || Amgen—Key Biologic Product Pipeline~ || Amgen SWOT Analysis~ | Sanofi—Biologic Product Pipeline Analysis ~ || Sanofi —Product Portfolio Overview~ || Sanofi —Key Biologic Product Pipeline~ || Sanofi SWOT Analysis~ | Abbvie—Biologic Product Pipeline Analysis ~ || Abbvie —Product Portfolio Overview~ || Abbvie —Key Biologic Product Pipeline~ || Abbvie SWOT Analysis~ | Novo Nordisk—Biologic Product Pipeline Analysis ~ || Novo Nordisk —Product Portfolio Overview~ || Novo Nordisk —Key Biologic Product Pipeline~ || Novo Nordisk SWOT Analysis~ | Merck & Co.—Biologic Product Pipeline Analysis ~ || Merck & Co —Product Portfolio Overview~ || Merck & Co —Key Biologic Product Pipeline~ || Merck & Co SWOT Analysis~ | Pfizer—Biologic Product Pipeline Analysis ~ || Pfizer —Product Portfolio Overview~ || Pfizer —Key Biologic Product Pipeline~ || Pfizer SWOT Analysis~ | Johnson & Johnson (JNJ)—Biologic Product Pipeline Analysis ~ || Johnson & Johnson (JNJ)—Product Portfolio Overview~ || Johnson & Johnson (JNJ)—Key Biologic Product Pipeline~ || Johnson & Johnson (JNJ) SWOT Analysis~ | Eli Lilly—Biologic Product Pipeline Analysis ~ || Eli Lilly—Product Portfolio Overview~ || Eli Lilly—Key Biologic Product Pipeline~ || Eli Lilly SWOT Analysis~ | GlaxoSmithKline (GSK)—Biologic Product Pipeline Analysis ~ || GlaxoSmithKline (GSK)—Product Portfolio Overview~ || GlaxoSmithKline (GSK)—Key Biologic Product Pipeline~ || GlaxoSmithKline (GSK) SWOT Analysis~ | Growth Environment—Business Models and Competitive Playbook~ || Business Models in Biologics Market~ || Competitive Playbook—Market Share Analysis~ || Top 10 Biologics in the Market~ || Top 10 Biologics Companies~ || Key Merger, Acquisition & Partnership Agreements~ || Key Investments and Facility Expansions~ | Growth Opportunities & Companies to Action~ || Transformation in Industry Ecosystem~ || 5 Major Growth Opportunities~ || Strategic Imperatives for Biologics Market~ | The Last Word~ || Conclusion—Key Take Aways~ || Legal Disclaimer~ | Appendix~ || List of Abbreviations~ | The Frost & Sullivan Story~
List of Charts and Figures 1. Biologics C2A: C2A Value Creators, Global, 2017~ 2. Roche: Key Marketed Biologics, Global, 2016~ 3. Amgen: Key Marketed Biologics, Global, 2016~ 4. Sanofi: Key Marketed Biologics, Global, 2016~ 5. Abbvie: Key Marketed Biologics, Global, 2016~ 6. Novo Nordisk: Key Marketed Biologics, Global, 2016~ 7. Global Biologics Market: Merck &Co, Key Marketed Products, Global, 2016~ 8. Global Biologics Market: Pfizer, Key Marketed Biologics, Global, 2016~ 9. Johnson & Johnson: Key Marketed Biologics, Global, 2016~ 10. Eli Lilly: Key Marketed Biologics, Global, 2016~ 11. GlaxoSmithKline: Key Marketed Biologics, Global, 2016~ 12. Total Biologics Market: Business Models, 2016~ 13. Total Biologics Market: Major Biologic Products, Global, 2016~ 14. Total Biologics Market: Leading Biologic Companies, Global, 2015~ 15. Total Biologics Market: Key Mergers and Acquisitions, Global, 2016-2017~ 16. Total Biologics Market: Facility Expansions and Investments, Global, 2016-17~ 17. Global Biologics Market: Major Growth Opportunities, Global, 2016–2021~| 1. Roche: Key Marketed Biologics, Global, 2016~ 2. Roche: Biologics by Development Phase, Global, 2017~ 3. Roche: Key Products in Development by Biologic Sub-segment, Global, 2017~ 4. Roche: Key Products in Development by Therapeutic Area, Global, 2017~ 5. Amgen: Key Marketed Biologics, Global, 2016~ 6. Amgen: Biologics by Development Phase, Global, 2017~ 7. Amgen: Key Products in Development by Biologic Sub-segment, Global, 2017~ 8. Amgen: Key Products in Development by Therapeutic Area, Global, 2017~ 9. Sanofi: Key Marketed Biologics, Global, 2016~ 10. Sanofi: Biologics by Development Phase, Global, 2017~ 11. Sanofi: Key Products in Development by Biologic Sub-segment, Global, 2017~ 12. Sanofi: Key Products in Development by Therapeutic Area, Global, 2017~ 13. Abbvie: Key Marketed Biologics, Global, 2016~ 14. Abbvie: Biologics by Development Phase, Global, 2017~ 15. Abbvie: Key Products in Development by Biologic Sub-segment, Global, 2017~ 16. Abbive: Key Products in Development by Therapeutic Area, Global, 2017~ 17. Novo Nordisk: Key Marketed Biologics, Global, 2016~ 18. Novo Nordisk: Biologics by Development Phase, Global, 2017~ 19. Novo Nordisk: Products in Development by Biologic Sub-segment, Global, 2017~ 20. Novo Nordisk: Key Products in Development by Therapeutic Area, Global, 2017~ 21. Merck & Co: Key Marketed Biologics, Global, 2016~ 22. Merck & Co: Biologics by Development Phase, Global, 2017~ 23. Merck & Co: Key Products in Development by Biologic Sub-segment, Global, 2017~ 24. Merck & Co: Key Products in Development by Therapeutic Area, Global, 2017~ 25. Pfizer: Key Marketed Biologics, Global, 2016~ 26. Pfizer: Biologics by Development Phase, Global, 2017~ 27. Pfizer: Products in Development by Biologic Sub-segment, Global, 2017~ 28. Pfizer: Key Products in Development by Therapeutic Area, Global, 2017~ 29. "Johnson & Johnson: Key Marketed Biologics, Global, 2016"~ 30. Johnson & Johnson: Biologics by Development Phase, Global, 2017~ 31. Johnson & Johnson: Products in Development by Biologic Sub-segment, Global, 2017~ 32. Johnson & Johnson: Key Products in Development by Therapeutic Area, Global, 2017~ 33. Eli Lilly: Key Marketed Biologics, Global, 2016~ 34. "Eli Lilly: Biologics by Development Phase, Global, 2017"~ 35. Eli Lilly: Key Products in Development by Biologic Sub-segment, Global, 2017~ 36. Eli Lilly: Key Products in Development by Therapeutic Area, Global, 2017~ 37. GlaxoSmithKline: Key Marketed Biologics, Global, 2016~ 38. GlaxoSmithKline: Biologics by Development Phase, Global, 2017~ 39. GlaxoSmithKline: Products in Development by Biologic Sub-segment, Global, 2017~ 40. GlaxoSmithKline: Key Products in Development by Therapeutic Area, Global, 2017~ 41. Global Pharmaceutical Market: Top Ten Drugs by Sales, Global, 2016~ 42. Total Genset Market for Water and Wastewater Treatment Plants: Revenue Breakdown by Genset Type, Global, 2016 and 2021~
Lightbox Content World Cancer Day 2019|Get 15% discount for all Healthcare studies |https://store.frost.com/contacts/?utm_source=PD&utm_medium=lightbox&utm_campaign=HEALTHCARE_CANCER2019
Author Unmesh Lal
Industries Healthcare
WIP Number MD83-01-00-00-00
Keyword 1 Biologic
Is Prebook No